Inyx, Inc., a specialty pharmaceutical company focused on niche drug delivery technologies and products, announced that its wholly owned UK subsidiary, Ashton Pharmaceuticals Ltd., has been selected by a British specialty pharmaceutical company to manufacture a new anti-anxiety drug for the market in the United Kingdom.

Ashton initially provided process development services to enable production scale up to commercial batch sizes on the new anti-anxiety drug. Ashton will now manufacture and package the entire production of this tablet product.

Jack Kachkar, M.D., chairman of Inyx, Inc., said, "We are very pleased that Inyx has been selected for the commercial production of this client's new product. This reflects Ashton's in-depth capabilities to enable clients to bring new products rapidly to market." Dr. Kachkar added that another new product of this client is also under discussion for Ashton.

Inyx, last August, acquired Ashton, which expanded Inyx's expertise into solid dose as well as injectable pharmaceuticals and enhanced its capabilities in dry powder inhalers. The company has another UK subsidiary, Inyx Pharma Ltd., which specializes in metered dose inhalers, metered dose nasal and oral sprays, hydrocarbon foam formulations and sterile saline solutions.